• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Zimmer Biomet debuts AI to predict post-operative recovery

Zimmer Biomet debuts AI to predict post-operative recovery

March 10, 2022 By Chris Newmarker

Zimmer Biomet WalkAI MyMobility artificial intelligence AI
When used over an iPhone, WalkAI can notify health professionals about predicted outcomes through the MyMobility clinician dashboard. [Image courtesy of ZB. Patients are fictitious.]
Zimmer Biomet (NYSE and SIX: ZBH) today launched WalkAI, artificial intelligence that can predict which patients will have lower gait speed 90 days after hip or knee surgery.

WalkAI is part of ZBEdge, Zimmer Biomet’s suite of integrated smart, digital and robotic technologies to boost patient outcomes after orthopedic surgeries.

The proprietary algorithm behind WalkAI analyzes a person’s mobility to generate a personalized daily prediction of their gait (walking) speed at 90 days after surgery. The daily predictions draw on extensive, anonymized, real-world data in the ZBEdge database.

“WalkAI is built from our wealth of anonymized ZBEdge data and is the first model to demonstrate our unique capability to deliver actionable predictions by connecting real-world data and AI through ZBEdge products and experiences,” said Liane Teplitsky, president of Global Robotics and Technology & Data Solutions at Zimmer Biomet.

The AI works with ZB’s MyMobility care management platform, which collects gait data through patients’ iPhones patient gait data. Then, when needed, it can notify health professionals through the MyMobility clinician dashboard.

Zimmer Biomet has rolled out WalkAI to a select group of MyMobility users. It will be widely available as part of ZBEdge by the end of the month.

“Our strategic prioritization and investment in R&D has solidified our position as an innovator in our space with breakthrough technologies like Persona IQ, a first-to-world smart knee implant, MyMobility care management platform, Rosa robotics, and now, WalkAI, the first AI-based model in orthopedics to create daily personalized outcome predictions based on a patient’s gait recovery,” said Zimmer Biomet COO Ivan Tornos.

Filed Under: Artificial Intelligence (AI), Digital Health, Featured, Health Information Technology, Health Technology, News Well, Orthopedics, Software / IT, Surgical Tagged With: Zimmer Biomet

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy